1
|
Coppry M, Duret S, Berdaï D, Miremont-Salamé G, Fourrier-Réglat A, Haramburu F, Rogues AM, Noize P. Adverse drug reactions induced by cotrimoxazole: Still a lot of preventable harm. Fundam Clin Pharmacol 2021; 36:421-426. [PMID: 34699080 DOI: 10.1111/fcp.12735] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Revised: 09/27/2021] [Accepted: 10/23/2021] [Indexed: 11/30/2022]
Abstract
Owing to a broad spectrum and low cost antimicrobial, cotrimoxazole is largely prescribed. However, its use is associated with various adverse drug reactions (ADRs) that warrant to ensure rational prescribing. This study aimed to describe spontaneous reports of cotrimoxazole ADRs and to evaluate the quality of prescription in patients who had ADRs. Suspected cotrimoxazole-induced ADRs cases reported to the Bordeaux regional pharmacovigilance center (France) during a 5-year period were described. Seriousness was assessed according to international criteria. Quality of prescription was assessed by compliance with the Summary of Product Characteristics (SPC) and relevance of cotrimoxazole indication. Then, an ADR was considered as preventable if the cotrimoxazole indication was not relevant, or potentially preventable if indication was relevant but the prescription was not compliant with the SPC. A total of 96 cases were analyzed: median age was 60.5 years (range: 4-94); 59.4% of patients were male. ADRs were mostly cutaneous disorders (n = 46) and hematological disorders (n = 25). A total of 60 serious ADRs occurred in 55 patients. Prescribers complied with all SPC recommendations in 21.9% of cases. Indication of cotrimoxazole was relevant or highly relevant in 41 cases. In 58% of cases, the occurrence of a cotrimoxazole-induced ADR would have been preventable or potentially preventable. In a context of increasing interest for this antibiotic to treat infections due to resistant bacteria, physicians should be more aware of the potential consequences of inappropriate prescribing cotrimoxazole and reserve its use when there is no alternative and under suitable monitoring.
Collapse
Affiliation(s)
- Maïder Coppry
- Inserm, BPH Research Center, Team Pharmacoepidemiology, UMR 1219, Univ. Bordeaux, Bordeaux, France.,Pôle de Santé Publique, Service de Pharmacologie médicale, CHU Bordeaux, Bordeaux, France.,Centre régional de Pharmacovigilance de Bordeaux, CHU Bordeaux, Bordeaux, France
| | - Stéphanie Duret
- Inserm, BPH Research Center, Team Pharmacoepidemiology, UMR 1219, Univ. Bordeaux, Bordeaux, France.,Pôle de Santé Publique, Service de Pharmacologie médicale, CHU Bordeaux, Bordeaux, France
| | - Driss Berdaï
- Inserm, BPH Research Center, Team Pharmacoepidemiology, UMR 1219, Univ. Bordeaux, Bordeaux, France.,Pôle de Santé Publique, Service de Pharmacologie médicale, CHU Bordeaux, Bordeaux, France
| | - Ghada Miremont-Salamé
- Inserm, BPH Research Center, Team Pharmacoepidemiology, UMR 1219, Univ. Bordeaux, Bordeaux, France.,Pôle de Santé Publique, Service de Pharmacologie médicale, CHU Bordeaux, Bordeaux, France.,Centre régional de Pharmacovigilance de Bordeaux, CHU Bordeaux, Bordeaux, France
| | - Annie Fourrier-Réglat
- Inserm, BPH Research Center, Team Pharmacoepidemiology, UMR 1219, Univ. Bordeaux, Bordeaux, France.,Pôle de Santé Publique, Service de Pharmacologie médicale, CHU Bordeaux, Bordeaux, France.,Inserm CIC1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Françoise Haramburu
- Inserm, BPH Research Center, Team Pharmacoepidemiology, UMR 1219, Univ. Bordeaux, Bordeaux, France.,Pôle de Santé Publique, Service de Pharmacologie médicale, CHU Bordeaux, Bordeaux, France.,Centre régional de Pharmacovigilance de Bordeaux, CHU Bordeaux, Bordeaux, France
| | - Anne-Marie Rogues
- Inserm, BPH Research Center, Team Pharmacoepidemiology, UMR 1219, Univ. Bordeaux, Bordeaux, France.,Pôle de Santé Publique, Service d'Hygiène hospitalière, CHU Bordeaux, Bordeaux, France
| | - Pernelle Noize
- Inserm, BPH Research Center, Team Pharmacoepidemiology, UMR 1219, Univ. Bordeaux, Bordeaux, France.,Pôle de Santé Publique, Service de Pharmacologie médicale, CHU Bordeaux, Bordeaux, France.,Centre régional de Pharmacovigilance de Bordeaux, CHU Bordeaux, Bordeaux, France.,Inserm CIC1401, Bordeaux PharmacoEpi, Bordeaux, France
| |
Collapse
|